Lipogranulomatosis

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
Status:
Not yet recruiting
Last Changed:
Jan 15, 2019
First Changed:
Jan 7, 2019
Disease(s):
BRAF NP_004324.2:p.V600X
Intervention(s):
Dabrafenib MesylateQuality-of-Life AssessmentQuestionnaire AdministrationTrametinib Dimethyl Sulfoxide
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Status:
Terminated
Last Changed:
Aug 7, 2013
First Changed:
Jun 28, 2011
Disease(s):
Cholestasis, Progressive Familial Intrahepatic 3
Intervention(s):
Yttrium microsphere injection
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Status:
Recruiting
Last Changed:
Sep 17, 2019
First Changed:
Mar 13, 2012
Disease(s):
Advanced Malignant Neoplasm
Intervention(s):
BevacizumabCetuximabLaboratory Biomarker AnalysisPharmacological StudyTemsirolimusValproic Acid

Connect. Empower. Inspire.